Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Dec 13;5(23):5420–5428. doi: 10.1182/bloodadvances.2021005507

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2021 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.

PMC Copyright notice

Figure 3. — Cumulative incidence and comparison of 6-MP dose in patients with SMNs after ALL. (A) Cumulative incidence of SMNs in 438 children in TCCSG L04-16 who received ALL therapy was significantly higher in patients with NUDT15 variants (3.0% at 7 years) than in those with wild-type alleles (0.3%; P = .045). P value was calculated using the Gray test. (B) Average daily dose of 6-MP in maintenance therapy for patients with SMNs with a NUDT15 heterozygous variant was significantly higher than the dose administered to control (CNTL) patients with the same NUDT15 genotype, but they did not develop SMNs after 6-MP–containing therapy in a previous study (P = .045). P value was calculated using the Mann-Whitney U test.